Serious adverse events derived from the drug interactions of antiretroviral therapy;Efectos secundarios graves derivados de las interacciones medicamentosas del tratamiento antirretroviral

Revista Clinica Espanola

Volumn 208, Issue 11, 2008, Pages 557-560

  Morales Conejo, M ^a   Moreno Cuerda, V J ^a   Abellan Martinez J ^a   Rubio, R ^b  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

cytochrome P 450; drug interactions; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450;

ADULT; ARTICLE; CASE REPORT; DRUG INTERACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MIDDLE AGED;

ADULT; ANTI-RETROVIRAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 65549151900     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(08)76033-8     Document Type: Article

References (11)

1. F.J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbility and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860
2. C. Pardo Rey, M. Yebra, M. Borrallo, A. Vega, A. Ramos, and M.C. Montero Irreversible coma, ergotamine, and ritonavir Clin Infect Dis 37 2003 72 73
3. C. Gallo, B. de la Fuente, M.L. García-Alcalde, and A. Antuña Ergotism in a patient treated with ritonavir and ergotamine Med Clin (Barc) 119 2002 558 559
4. Ficha Técnica Seretide. EMEA 2007.
5. K. Samaras, S. Pett, A. Gowers, M. McMurchie, and D.A. Cooper Iatrogenic Cushing's syndrome with osteoporosis and secundary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases J Clin Endocrinol Metab 90 2005 4394 4398
6. M.J. Gillett, P.U. Cameron, H.V. Nguyen, D.M. Hurley, and S.A. Mallal Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone AIDS 19 2005 740 741
7. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetics (PK) of omeprazole on atazanavir with ritonavir in healthy subjects. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005. Abstract 658.
8. A.D. Luber, R. Brower, D. Kim, R. Silverman, C.A. Peloquin, and I. Frank Steadystate pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers HIV Medicine 8 2007 457 464
9. Agarwala S, Eley T, Child M, et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. 6th International Workshop on Pharmacology of HIV Therapy. Quebec City, Quebec, Canadá, April 2005. Abstract 11.
10. G.K. Dresser, J.D. Spence, and D.G. Bailey Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 38 2000 41 57
11. Panel de expertos de Gesida y Plan Nacional del Sida. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Disponible en: wwww.gesida.seimc.org